Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-272-6138
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees18
Next Earnings Date8/9/2019 (Estimated)
OptionableNot Optionable
Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions
What is Eiger Biopharmaceuticals' stock symbol?
Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."
How were Eiger Biopharmaceuticals' earnings last quarter?
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) announced its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.90) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.95) by $0.05. View Eiger Biopharmaceuticals' Earnings History.
When is Eiger Biopharmaceuticals' next earnings date?
What price target have analysts set for EIGR?
6 brokers have issued 1 year price objectives for Eiger Biopharmaceuticals' stock. Their predictions range from $24.00 to $47.00. On average, they expect Eiger Biopharmaceuticals' share price to reach $34.50 in the next year. This suggests a possible upside of 202.1% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.
What is the consensus analysts' recommendation for Eiger Biopharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.
What are Wall Street analysts saying about Eiger Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (5/1/2019)
- 2. Wedbush analysts commented, ". Reiterate OW and $130 PT. FINCH 1 & 3 Ph3 filgotinib data, expected any day now, is an important catalyst for GLPG and partner GILD (Young, OW). Our thoughts on what to look for. The first filgotinib Ph3 study, FINCH 2, read out in Sept. ’18 and in our view suggested that filgotinib may have a best in class risk-benefit profile among the JAK inhibitors. In the data from the FINCH 1 & 3 studies (guided for 1Q19), we think investors will be focused on 1) how efficacy compares to other agents, most notably upadacitinib (ABBV, not- covered), 2) safety events such as thrombotic events/infections vs. placebo. For our detailed RA trial comp." (3/26/2019)
Has Eiger Biopharmaceuticals been receiving favorable news coverage?
Media coverage about EIGR stock has trended somewhat negative this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eiger Biopharmaceuticals earned a news impact score of -1.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Eiger Biopharmaceuticals' key competitors?
Some companies that are related to Eiger Biopharmaceuticals include Autolus Therapeutics (AUTL), MeiraGTx (MGTX), BAVARIAN NORDIC/S (BVNRY), Twist Bioscience (TWST), Nightstar Therapeutics (NITE), Cellectis (CLLS), Chiesi USA (CRTX), Vericel (VCEL), Precision BioSciences (DTIL), Osiris Therapeutics (OSIR), Adverum Biotechnologies (ADVM), Heska (HSKA), DBV TECHNOLOGIE/S (DBVT), Scholar Rock (SRRK) and Acorda Therapeutics (ACOR).
What other stocks do shareholders of Eiger Biopharmaceuticals own?
Who are Eiger Biopharmaceuticals' key executives?
Eiger Biopharmaceuticals' management team includes the folowing people:
- Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)
- Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)
- Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)
- Mr. James P. Shaffer, Chief Bus. Officer (Age 52)
- Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 38)
Who are Eiger Biopharmaceuticals' major shareholders?
Eiger Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Interwest Venture Management Co. (3.99%), BlackRock Inc. (2.35%), Renaissance Technologies LLC (1.45%), Broadfin Capital LLC (1.00%), P.A.W. Capital Corp (0.99%) and Fosun International Ltd (0.75%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Jeffrey S Glenn, Joanne Quan, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Institutional Ownership Trends for Eiger Biopharmaceuticals.
Which institutional investors are selling Eiger Biopharmaceuticals stock?
EIGR stock was sold by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., Oxford Asset Management LLP, Algert Global LLC, Acadian Asset Management LLC, Fosun International Ltd, P.A.W. Capital Corp, Dimensional Fund Advisors LP and BlackRock Inc.. View Insider Buying and Selling for Eiger Biopharmaceuticals.
Which institutional investors are buying Eiger Biopharmaceuticals stock?
EIGR stock was acquired by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Broadfin Capital LLC, JPMorgan Chase & Co., Tibra Equities Europe Ltd, Citigroup Inc., Renaissance Technologies LLC, ExodusPoint Capital Management LP and Wedbush Securities Inc.. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Insider Buying and Selling for Eiger Biopharmaceuticals.
How do I buy shares of Eiger Biopharmaceuticals?
Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eiger Biopharmaceuticals' stock price today?
One share of EIGR stock can currently be purchased for approximately $11.42.
How big of a company is Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals has a market capitalization of $219.95 million. The biotechnology company earns $-52,390,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.
What is Eiger Biopharmaceuticals' official website?
How can I contact Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]
MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
